Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
ASCEND-7
A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
- NCT02336451 ↗
- Completed
- Novartis Pharmaceuticals
- Focused
We haven't built an HCP commentary report on ASCEND-7 (ceritinib in ALK-positive NSCLC metastatic to brain and/or leptomeninges) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ASCEND-7 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges
- Phase
- Phase 2
- Status
- Completed
- Conditions
- ALK-positive Non-small Cell Lung Cancer
- Interventions
- Ceritinib
- Arms
- Arm 1 (PrALKi=Y, PrBRad=Y) · Experimental
- Arm 2 (PrALKi=Y, PrBRad=N) · Experimental
- Arm 3 (PrALKi=N, PrBRad=Y) · Experimental
- Arm 4 (PrALKi=N, PrBRad=N) · Experimental
- Arm 5 (LepDis) · Experimental
- Enrollment
- 156
- Primary outcomes
- Overall Response Rate (ORR) Per Investigator Assessment
- Sponsor
- Novartis Pharmaceuticals
- Start
- Apr 1, 2015
- Primary completion
- Feb 6, 2019
- Results posted
- Yes
- Registry record
- NCT02336451 · updated Apr 21, 2020
Publications
linked from the registry- Chow LQM, Barlesi F, Bertino EM, van den Bent MJ, Wakelee HA, Wen PY, Chiu CH, Orlov S, Chiari R, Majem M, McKeage M, Yu CJ, Garrido P, Hurtado FK, Arratia PC, Song Y, Branle F, Shi M, Kim DW. ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients with ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges. Clin Cancer Res. 2022 Jun 13;28(12):2506-2516. doi: 10.1158/1078-0432.CCR-21-1838. PubMed 35091443